A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 35/00 (2006.01) A61K 31/565 (2006.01) A61K 31/70 (2006.01) A61K 31/7048 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2362047
This invention provides for a novel schedule and dosage regimen of the combination paclitaxel-estramustine and chemical or surgical androgen depletion to treat patients with advanced prostate cancer who have not received previous therapy and are candidates for hormonal therapy. This invention differs from all current treatment strategies by the intercalation of cytotoxic chemotherapy (preferably paclitaxel and estramustine) at a specified interval (two months; range 1-6 months) after initiation of androgen depletion therapy.
Cette invention concerne un régime à programme et à dosage se servant de la combinaison paclitaxel-estramustine et de la déplétion chimique ou chirurgicale androgène pour traiter des patients atteints d'un cancer de la prostate avancé, qui n'ont préalablement pas suivi d'autre thérapie et se portent volontaires pour une thérapie hormonale. Cette invention se distingue des stratégies de traitement adoptées actuellement par l'interposition d'une chimiothérapie cytotoxique (de préférence au moyen de paclitaxel et d'estramustine) à intervalles réguliers (2 mois; de 1 à 6 mois) après le début de la thérapie par déplétion hormonale.
Napro Biotherapeutics Inc.
Sim & Mcburney
LandOfFree
Treatment regimen for prostate cancer, initiated after... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment regimen for prostate cancer, initiated after..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment regimen for prostate cancer, initiated after... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1438907